2. Protein Tyrosine Kinase/RTK Apoptosis
  3. VEGFR Apoptosis
  4. Anti-Mouse VEGFR-2 Antibody (DC101)

Anti-Mouse VEGFR-2 Antibody (DC101) 

目录号: HY-P990106 纯度: 99.41%
COA 技术支持

Anti-Mouse VEGFR-2 Antibody (DC101) 是一种大鼠来源抗小鼠 VEGFR2 单克隆抗体。Anti-Mouse VEGFR-2 Antibody (DC101) 通过阻断 VEGF 和 VEGFR2 的结合来抑制肿瘤血管生成。Anti-Mouse VEGFR-2 Antibody (DC101) 促进免疫细胞浸润并诱导肿瘤细胞凋亡 (apoptosis)。Anti-Mouse VEGFR-2 Antibody (DC101) 可用于多种癌症的研究如黑色素瘤，肺癌和乳腺癌。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥900
In-stock
5 mg ￥3600
In-stock
10 mg ￥6150
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Anti-Mouse VEGFR-2 Antibody (DC101) 相关抗体

Top Publications Citing Use of Products

查看 VEGFR 亚型特异性产品:

查看所有亚型
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for research on various types of cancer such as melanoma, lung cancer and breast cancer [1][2][3][4][5][6].

同型

Rat IgG1 kappa
推荐同型对照抗体
IC50 & Target[1][2][3][4][5][6]

VEGFR2

 

体内研究
(In Vivo)

Anti-Mouse VEGFR-2 Antibody (DC101) (1 mg/剂量, 腹腔注射, 每周两次, 持续 4 周) 显著诱携带 253J B-V 肿瘤的雄性无胸腺 BALB/c 裸鼠的肿瘤细胞和内皮细胞凋亡，并显著抑制血管生成[1]。
Anti-Mouse VEGFR-2 Antibody (DC101) (10 mg/kg, 腹腔注射, 在第 2、5 和 8 天) 显著抑制了携带 H22 肿瘤的雌性 BALB/c 小鼠的肿瘤生长且没有明显的毒性[2]。
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg, 腹腔注射, 每三天一次, 持续 4 周) 显著抑制了携带 B16-OVA 肿瘤的雌性 C57BL/6 小鼠的肿瘤生长并增加了免疫细胞浸润[3]。
Anti-Mouse VEGFR-2 Antibody (DC101) (40 mg/kg, 腹腔注射, 每周三次, 持续 21 天) 显著抑制表达 HPV8 CER 的转基因小鼠的伤口诱导的肿瘤生长[4]。
Anti-Mouse VEGFR-2 Antibody (DC101) (0.8 mg/小鼠, 腹腔注射, 每周两次, 持续 2-3 周) 抑制 FVB 小鼠和携带 NT2.5 肿瘤的 Neu-N 小鼠的肿瘤生长并增加 T 细胞浸润[5]。
Anti-Mouse VEGFR-2 Antibody (DC101) (100 或 400μg, 腹腔注射, 每三天一次, 持续 21 天) 显著降低了注射 bFGF 和 VEGF 的雌性 C57BL/6 小鼠的血管生成和内皮细胞数量[6]。
Anti-Mouse VEGFR-2 Antibody (DC101) (800 μg, 腹腔注射, 每三天一次) 显著抑制各种肿瘤的生长[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 1×106 253J B-V cells injected male athymic BALB/c nude mice (8-12 weeks)[1]
Dosage: 1 mg/dose, combinated with Paclitaxel (HY-B0015) 10 mg/kg
Administration: Intraperitoneal injection (i.p.), twice weekly for 4 weeks
Result: Significantly prolonged the survival period of mice.
Significantly reduced tumor microvascular density.
Enhanced apoptosis of tumor cells and endothelial cells.
Animal Model: 2×106 H22 cells injected female BALB/c mice (6-8 weeks, 20 g)[2]
Dosage: 10 mg/kg, combinated with CA4 NPs (45 mg/kg) and anti-PD-1 (100 μg/mouse)
Administration: Intraperitoneal injection (i.p.) on day 2, 5 and 8
Result: Increased the number of CD8+ T cells within the tumor.
Significantly improved vascular perfusion.
Reduced the level of IFN-γ and TNF-α.
Had good safety in vivo.
Animal Model: 5×105 B16-OVA cells injected female C57BL/6 mice (6-8 weeks)[3]
Dosage: 40 mg/kg
Administration: Oral gavage (i.g.), once every three days for 4 weeks
Result: Significantly inhibited tumor volume.
Increased infiltration of CD3+ and CD8+ T cells.
Increased infiltration of B cells (CD19+) and dendritic cells (CD11c+).
Enhanced the expression of IFN-γ, perforin, and granzyme B in CD8+ T cells.
Reduced vascular density and increased perivascular cell coverage.
Significantly increased the density of PNAd+HEV and promoted the formation of tertiary lymphoid structures (TLS).
Upregulated PD-L1 expression in tumor cells and CD45+ immune cells, as well as PD-1 expression in CD3+ T cells.
Animal Model: Transgenic mice expressing CER of HPV8[4]
Dosage: 40 mg/kg
Administration: Intraperitoneal injection (i.p.), three times every week for 21 days
Result: Reduce Ki-67+ proliferating cells and CD31+ vascular density.
Animal Model: 5×106 NT2.5 cells injected FVB mice and Neu-N mice[5]
Dosage: 0.8 mg/mouse
Administration: Intraperitoneal injection (i.p.), twice weekly for 2-3 weeks
Result: Increased CD4+ and CD8+ T cell infiltration.
Significantly inhibited tumor volume.
Decreased angiogenesis and increased tumor cell apoptosis.
Animal Model: Female C57BL/6 injected with bFGF (500 ng) and VEGF (10 μg)[6]
Dosage: 100 or 400 μg
Administration: Intraperitoneal injection (i.p.), once every three days for 21 days
Result: Significantly reduced angiogenesis and endothelial cell count in matrigel plug model.
Animal Model: 2×106 Lewis lung cells or 1×105 B16 cells injected female C57BL/6 mice (5-6 weeks), 1×105 4T1 cells injected female BALB/c mice (5-6 weeks), 2×106 A431, SK-RC-29, BxPC-3 or GBM-18 cells injected female athymic nu/nu mice (5-6 weeks)[6]
Dosage: 800 μg
Administration: Intraperitoneal injection (i.p.), once every three days
Result: Significantly inhibited tumor growth.
基因 ID

16542  [NCBI]

Accession
应用

ELISA, FACS, Functional assay, Research in vivo
偶联物

Unconjugated
复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.
分子量

150 kDa

性状

液体

颜色

Colorless to light yellow

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
  • Immobilized VEGFR-2/Flk-1/KDR Fc Chimera Protein, Mouse can bind Anti-Mouse VEGFR-2 Antibody (DC101). The EC50 for this effect is 177.8 ng/mL.
纯度 & 产品资料

纯度: 99.41%

COA (266 KB) SDS-PAGE (84 KB) SEC-HPLC (218 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Anti-Mouse VEGFR-2 Antibody (DC101) 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Mouse VEGFR-2 Antibody (DC101)VEGFRApoptosisVascular endothelial growth factor receptorVEGFR2apoptosismelanomalung cancerprostate cancerbreast cancerhepatocellular carcinomaInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Anti-Mouse VEGFR-2 Antibody (DC101)
目录号：
HY-P990106
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z